Tumor Suppressor Gene-based Nanotherapy: from Test Tube to the Clinic

Overview

Journal J Drug Deliv

Date 2011 Apr 15

PMID 21490751

Citations 8

Authors

Manish Shanker

Jiankang Jin

Cynthia D Branch

Shinya Miyamoto

Elizabeth A Grimm

Jack A Roth

Rajagopal Ramesh

Affiliations

Soon will be listed here.

Abstract

Cancer is a major health problem in the world. Advances made in cancer therapy have improved the survival of patients in certain types of cancer. However, the overall five-year survival has not significantly improved in the majority of cancer types. Major challenges encountered in having effective cancer therapy are development of drug resistance by the tumor cells, nonspecific cytotoxicity, and inability to affect metastatic tumors by the chemodrugs. Overcoming these challenges requires development and testing of novel therapies. One attractive cancer therapeutic approach is cancer gene therapy. Several laboratories including the authors' laboratory have been investigating nonviral formulations for delivering therapeutic genes as a mode for effective cancer therapy. In this paper the authors will summarize their experience in the development and testing of a cationic lipid-based nanocarrier formulation and the results from their preclinical studies leading to a Phase I clinical trial for nonsmall cell lung cancer. Their nanocarrier formulation containing therapeutic genes such as tumor suppressor genes when administered intravenously effectively controls metastatic tumor growth. Additional Phase I clinical trials based on the results of their nanocarrier formulation have been initiated or proposed for treatment of cancer of the breast, ovary, pancreas, and metastatic melanoma, and will be discussed.

Citing Articles

Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management.

Allemailem K, Almatroodi S, Almatroudi A, Alrumaihi F, Al Abdulmonem W, Al-Megrin W Int J Mol Sci. 2023; 24(8).

PMID: 37108214 PMC: 10139162. DOI: 10.3390/ijms24087052.

Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.

Allemailem K, Alsahli M, Almatroudi A, Alrumaihi F, Alkhaleefah F, Rahmani A Cancer Commun (Lond). 2022; 42(12):1257-1287.

PMID: 36209487 PMC: 9759771. DOI: 10.1002/cac2.12366.

Innovative approaches for cancer treatment: current perspectives and new challenges.

Pucci C, Martinelli C, Ciofani G Ecancermedicalscience. 2019; 13:961.

PMID: 31537986 PMC: 6753017. DOI: 10.3332/ecancer.2019.961.

The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines.

Gutierrez-Lovera C, Vazquez-Rios A, Guerra-Varela J, Sanchez L, de la Fuente M Genes (Basel). 2017; 8(12).

PMID: 29182542 PMC: 5748667. DOI: 10.3390/genes8120349.

Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth and By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.

Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao Y Mol Cancer Ther. 2017; 16(8):1470-1486.

PMID: 28572169 PMC: 5544587. DOI: 10.1158/1535-7163.MCT-17-0134.

References

Prudkin L, Behrens C, Liu D, Zhou X, Ozburn N, Bekele B . Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008; 14(1):41-7. PMC: 2833352. DOI: 10.1158/1078-0432.CCR-07-1252. View

Ramesh R, Ito I, Saito Y, Wu Z, Mhashikar A, Wilson D . Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2005; 23(12):850-7. DOI: 10.1089/dna.2004.23.850. View

Marshall E . Gene therapy death prompts review of adenovirus vector. Science. 2000; 286(5448):2244-5. DOI: 10.1126/science.286.5448.2244. View

Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C . Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002; 62(9):2715-20. PMC: 3478680. View

Yew N, Wang K, Przybylska M, Bagley R, Stedman M, Marshall J . Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther. 1999; 10(2):223-34. DOI: 10.1089/10430349950019011. View

Nemunaitis J, Swisher S, Timmons T, Connors D, Mack M, Doerksen L . Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000; 18(3):609-22. DOI: 10.1200/JCO.2000.18.3.609. View

Mady M, Ghannam M, Khalil W, Repp R, Markus M, Rascher W . Efficient gene delivery with serum into human cancer cells using targeted anionic liposomes. J Drug Target. 2004; 12(1):11-8. DOI: 10.1080/10611860410001683059. View

Ramesh R . Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008; 433:301-31. DOI: 10.1007/978-1-59745-237-3_19. View

Xu L, Huang C, Huang W, Tang W, Rait A, Yin Y . Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002; 1(5):337-46. View

10.

Yezhelyev M, Gao X, Xing Y, Al-Hajj A, Nie S, ORegan R . Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006; 7(8):657-67. DOI: 10.1016/S1470-2045(06)70793-8. View

11.

Ramezani M, Khoshhamdam M, Dehshahri A, Malaekeh-Nikouei B . The influence of size, lipid composition and bilayer fluidity of cationic liposomes on the transfection efficiency of nanolipoplexes. Colloids Surf B Biointerfaces. 2009; 72(1):1-5. DOI: 10.1016/j.colsurfb.2009.03.018. View

12.

Hung M, Hortobagyi G, Ueno N . Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol. 2000; 465:171-80. DOI: 10.1007/0-306-46817-4_16. View

13.

Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati B, Kompella U . Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009; 15(23):7299-308. PMC: 2787834. DOI: 10.1158/1078-0432.CCR-09-1745. View

14.

Devalapally H, Shenoy D, Little S, Langer R, Amiji M . Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol. 2006; 59(4):477-84. DOI: 10.1007/s00280-006-0287-5. View

15.

Templeton N, Lasic D, Frederik P, Strey H, Roberts D, Pavlakis G . Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997; 15(7):647-52. DOI: 10.1038/nbt0797-647. View

16.

Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch C . Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004; 11(11):733-9. DOI: 10.1038/sj.cgt.7700756. View

17.

Ito I, Began G, Mohiuddin I, Saeki T, Saito Y, Branch C . Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther. 2003; 7(3):409-18. DOI: 10.1016/s1525-0016(03)00004-2. View

18.

Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

19.

Lohmann D . Retinoblastoma. Adv Exp Med Biol. 2010; 685:220-7. DOI: 10.1007/978-1-4419-6448-9_21. View

20.

Yang Y, Jooss K, Su Q, Ertl H, Wilson J . Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996; 3(2):137-44. View